Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Olivier Antoine M. Charmeil
CEOOlivier Antoine M. Charmeil
Employees
76,493
Employees76,493
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
76,493
Employees76,493

SNY Key Statistics

Market cap
117.38B
Market cap117.38B
Price-Earnings ratio
19.42
Price-Earnings ratio19.42
Dividend yield
3.42%
Dividend yield3.42%
Average volume
3.50M
Average volume3.50M
High today
$48.35
High today$48.35
Low today
$47.40
Low today$47.40
Open price
$47.54
Open price$47.54
Volume
3.02M
Volume3.02M
52 Week high
$55.77
52 Week high$55.77
52 Week low
$43.32
52 Week low$43.32

SNY News

TipRanks 10h
Sanofi Builds Immunology Momentum with March 2026 Wave of Global Approvals and Data

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Nasdaq 4d
Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis

(RTTNews) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trials—COAST 1, COAST 2, and SHORE—evaluating amlitelimab, a...

Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis
Simply Wall St 4d
AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

AstraZeneca reported that its antibody drug tozorakimab succeeded in two Phase 3 trials in chronic obstructive pulmonary disease (COPD), targeting a broad COPD...

AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

More SNY News

TipRanks 6d
Innate Pharma Posts 2025 Results, Flags H2 2026 CTCL Phase 3 Start Amid Cash Runway to Q3

The latest announcement is out from Innate Pharma SA ( (FR:IPH) ). Innate Pharma on March 26, 2026 reported full-year 2025 results, highlighting pipeline progr...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.